Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesInfectious DiseaseBlue Cross Blue Shield LA HIV Coverage Update | Op…
    Ask Trek AI about this page
    Modifiedblue cross blue shield - louisianaPolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)

    Human Immunodeficiency Virus (HIV)

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - M2116 - Human Immunodeficiency Virus (HIV) alerts

    Get alerted when Policy AHS - M2116 - Human Immunodeficiency Virus (HIV) changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, limitations, and clinical background for HIV screening, confirmatory testing, nucleic acid testing, viral load monitoring, and genotypic/phenotypic resistance assays for affected individuals and providers.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHuman Immunodeficiency Virus (HIV)
    Policy CodePolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)
    Change TypeCoverage criteria revisions and code removal
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionOrder antigen/antibody combination assay (or rapid antibody test for PrEP populations) for screening and document risk factors and indication when requesting testing.
    SourceLink
    POLICY UPDATE CHANGES

    Addition of new CC9: '9) Screening for HIV-1 and HIV-2 using an antibody test that does not provide rapid results and does not incorporate antigen testing DOES NOT MEET COVERAGE CRITERIA.'

    Removed CPT code 86689.

    New CC3 and CC4 clarifying PrEP-related screening and antibody differentiation assay coverage: screening with antigen/antibody combination assay or rapid antibody test for PrEP populations meets criteria; HIV-1/HIV-2 antibody differentiation assay meets criteria if initial screening positive.

    Frequency limits and test-type clarifications moved into new Note 1 and Note 2 describing repeat testing intervals and lists of risk factors; antigen testing alone does not meet criteria.

    Initial & repeatHIV antigen/antibody screening coverage
    NAT allowedNucleic acid testing coverage
    Doravirine: requiredDrug resistance testing requirement
    Not coveredNot covered: antibody-only tests
    90d / 1moTesting frequency limits
    9Recent coverage changes

    Coverage Criteria — Screening, Diagnostic, and Resistance Testing

    inv-01: Screening and Diagnostic Testing

    Covered when the following conditions are met:

    Screening age-based: Initial screening with an antigen/antibody combination assay for individuals 11 to 65 years of age
    Repeat screening: Repeat antigen/antibody screening for individuals 11 to 65 years of age meets coverage

    See Note 1 for frequency limits

    High-risk or PrEP-associated screening: Individuals initiating or receiving PrEP or with elevated risk factors may be screened with an antigen/antibody combination assay or a rapid antibody test

    See Note 2 for risk factors and Note 1 for frequency limits

    inv-02: Confirmatory and Nucleic Acid Testing

    Covered when ANY of the following apply:

    Ab-positive initial screening: HIV-1/HIV-2 antibody differentiation assay for individuals with a positive initial antigen/antibody screening test

    See Note 1 for frequency limits

    Indeterminate or recent-exposure: Nucleic acid testing (qualitative or quantitative) for individuals with indeterminate or positive initial screening, or for those with suspected recent exposure

    NAT repeat interval: not more often than once every month; collect new specimen to confirm before initiating ART when indicated

    Infant diagnostic testing: Plasma quantification of HIV-1 or HIV-2 RNA for infants younger than 18 months born to HIV-positive mothers

    Antibody tests may be confounded by maternal antibodies in this age group

    inv-03: Genotyping and Phenotyping (Resistance Testing)

    Genotypic or phenotypic testing meets coverage criteria for any of the following situations:

    Doravirine pre-initiation: Genotyping and phenotyping required prior to initiating doravirine therapy

    Phenotyping specifically required per policy

    Therapy failure or suboptimal response: Individuals who have failed a course of antiviral therapy, have suboptimal viral load reduction, or are noncompliant with therapy

    Genotypic testing preferred; add phenotypic testing for suspected multidrug resistance or complex patterns

    Treatment guidance for recent infection: To guide treatment decisions in acute or recent infection (within last 6 months) and for antiretroviral‑naïve individuals entering care

    Do not delay ART initiation for results; modify regimen once results available

    Pregnancy indications:

    inv-04: DHHS-aligned coverage criteria

    Covered when ALL of the following DHHS-recommended conditions are met

    Initial evaluation: Viral load and CD4 count measured at entry into care; genotypic resistance testing sent before initiation of ARTentry into care

    Do not delay ART initiation for resistance results

    Post-initiation monitoring: Plasma viral load measured within 4–8 weeks after ART initiation and every 4–8 weeks until below assay limit of detection; thereafter every 3–4 months or up to 6 months if clinically stable4–8 weeks; 3–4 months (extend to 6 months if stable)

    Follow DHHS monitoring intervals

    Virologic failure testing: Perform genotypic resistance testing for persons with virologic failure (>200 copies/mL) and include integrase gene when INSTI resistance is suspected or prior CAB-LA exposure occurred>200 copies/mL

    inv-05: Resistance testing for virologic failure

    Covered when ALL of the following are met

    Resistance testing in virologic failure: Genotypic resistance testing (reverse transcriptase and protease) should be performed for everyone with virologic failure; perform INSTI resistance testing for virologic failure on INSTI-based regimensvirologic failure as defined by guideline thresholds (e.g., >200 copies/mL)

    Order INSTI assays separately if needed; perform testing while on ART or within 4 weeks of stopping non‑long‑acting agents; for long‑acting agents test regardless of time since discontinuation

    inv-06: Diagnostic testing

    Covered when ALL of the following are met

    Diagnostic testing and follow-up: Initial diagnostic testing should use a fourth‑generation HIV antigen/antibody assay with confirmatory antibody differentiation; if negative/indeterminate with high clinical suspicion use an HIV‑1 NATper CDC algorithms and window periods

    Rapid testing may be used when expedited results are needed (e.g., PrEP initiation); collect new specimen to confirm diagnosis before initiating ART when indicated

    inv-07: Resistance testing modality

    Covered when ALL of the following are met

    Use of phenotypic vs genotypic testing: Genotypic testing is preferred for most patients; add phenotypic testing when complex or suspected complex resistance patterns existknown or suspected complex mutation patterns

    Review prior and current resistance tests when constructing new regimens; proviral DNA genotyping may be useful in select circumstances but is not routinely recommended

    inv-08: HIV-2 monitoring

    Covered when ALL of the following are met

    HIV-2 viral load monitoring: If pre-treatment HIV-2 viral load is detectable: measure at 1, 3, and 6 months after starting or changing ART, then every 3–6 months; if pre-treatment undetectable: measure at 1 month then every 6 monthspre-treatment detectable vs undetectable

    Repeat viral load and perform resistance testing if viral load becomes repeatedly detectable after maximal suppression

    HIV-2 resistance testing indication: Perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure when HIV-2 viral load meets threshold>=500 copies/mL

    Per BHIVA and policy guidance

    inv-09: Testing and monitoring criteria

    Covered when testing and monitoring follow evidence-based timing and indications

    Investigation of indeterminate serology: When HIV-1 or HIV-2 serology does not fit a clear confirmed diagnosis, PCR for HIV-2 proviral DNA should be performed to establish presence or absence of HIV-2 infection

    Document investigation and include PCR for HIV‑2 proviral DNA as indicated

    Viral load monitoring schedules: If pre-treatment viral load is detectable: measure at 1, 3, and 6 months after starting or changing ART, then every 3–6 months. If pre-treatment viral load is undetectable: measure at 1 month then every 6 months

    Follow DHHS and other society guidance for intervals; document timing of measurements

    Resistance testing indications: Perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure when thresholds are met (including HIV-2 threshold of ≥500 copies/mL); proviral DNA genotyping may be useful in select circumstances but is not routinely recommended>=500 copies/mL for HIV-2; >200 copies/mL for HIV-1 virologic failure considerations

    inv-10: Summary of recently added/changed coverage criteria

    Policy coverage changes described in revision history — select highlights:

    CC3_PrEP_Screening: For individuals who will begin PrEP, those receiving PrEP, or individuals with elevated risk factors, screening with an antigen/antibody combination assay or a rapid antibody test MEETS COVERAGE CRITERIA.

    Added as CC3 in revision history

    CC4_AntibodyDifferentiation: For individuals with a positive initial screening test, the HIV-1/HIV-2 antibody differentiation assay MEETS COVERAGE CRITERIA.

    Added as CC4 in revision history

    CC9_AntibodyOnlyNotCovered: Screening using an antibody test that does not provide rapid results and does not incorporate antigen testing DOES NOT MEET COVERAGE CRITERIA.

    Added as CC9 in revision history; removed outdated antibody-only screening methods

    TestingFrequencyLimits:

    Routine simultaneous ordering of both genotypic and phenotypic resistance assays is not supported by the evidence and DOES NOT MEET COVERAGE CRITERIA. The policy specifically states that routine use of combined genotyping and phenotyping does not meet coverage criteria, and that drug-susceptibility phenotype prediction using genotypic comparison to databases does not meet coverage criteria (lack of sufficient published literature demonstrating clinical benefit). Providers should order genotypic or phenotypic testing only when indicated by the covered clinical scenarios (e.g., treatment failure, pre-doravirine evaluation, suspected multidrug resistance), and document the clinical rationale when phenotypic testing is requested for complex resistance patterns.

    A modeled economic evaluation referenced in the policy found that using point-of-care HIV RNA testing to guide mode of delivery for women without prenatal care was associated with higher costs and more HIV-infected neonates compared with routine cesarean delivery for all. The analysis concluded point-of-care viral-load–guided delivery increased cost and decreased effectiveness under most modeled assumptions, and therefore routine use of point-of-care RNA testing for mode-of-delivery decision-making is not supported by this evidence.

    Per International Antiviral Society guidance cited in the policy, proviral (proviral DNA) resistance testing is not required prior to switching to two‑drug therapy unless there is a documented or suspected history of treatment failure. The guidance also supports switching virologically suppressed patients from long-acting cabotegravir plus rilpivirine back to daily oral therapy without proviral DNA testing when suppression has been maintained; document prior treatment history and any concerns for archived resistance when considering testing.

    The policy references the European AIDS Clinical Society statement that routine proviral DNA genotyping is currently not recommended. Proviral DNA assays can fail to detect prior resistance mutations and may detect archived mutations of uncertain clinical significance; therefore proviral testing should be reserved for specific circumstances (for example, multiple prior virologic failures, unavailable resistance history, or low-level viremia at the time of switch) and results interpreted cautiously.

    HIV antigen testing ordered alone (separate from an antigen/antibody combination assay) is explicitly noncovered in this policy: HIV antigen testing independent of antigen/antibody testing DOES NOT MEET COVERAGE CRITERIA. In addition, the policy clarifies that screening with antibody-only tests that are non-rapid and lack antigen detection DOES NOT MEET COVERAGE CRITERIA for initial screening, and providers should use an antigen/antibody combination assay or an appropriate rapid antibody test per the coverage criteria.

    The policy reiterates that routine combined genotyping and phenotyping does not meet coverage criteria and that computational phenotype prediction from genotypic comparisons to databases is not an accepted substitute for clinically indicated testing. Genotypic testing is preferred for most clinical situations; phenotypic assays are covered only when clinically justified (for example, suspected multidrug resistance or complex mutation patterns) and should be ordered with documentation of the specific clinical indication.

    When considering mode-of-delivery decisions, the policy cites modeling and guideline context indicating limited value for routine point-of-care viral-load testing compared with established delivery strategies. The referenced modeling found point-of-care RNA-guided delivery increased costs and neonatal infections versus routine cesarean delivery, and professional guidance (e.g., SMFM/ACOG context) supports third-trimester viral-load assessment and a cesarean-planning threshold of ≥1000 copies/mL rather than relying on point-of-care RNA testing as a universal delivery decision tool.

    For intrapartum or peripartum decision-making, rapid diagnostic pathways are available when maternal HIV status is undocumented, but the policy notes that modelling and guideline evidence do not support routine point-of-care viral-load testing to change mode of delivery for all patients. When viral-load measurement is used in delivery planning, follow established thresholds and timing (for example, third-trimester assessment and the ≥1000 copies/mL threshold informing cesarean recommendations) rather than routine point-of-care RNA testing for every case.

    The policy aligns with international guidance that proviral resistance testing is not required when switching virologically suppressed patients back to oral therapy from long-acting injectables (e.g., cabotegravir plus rilpivirine) provided suppression has been maintained and there is no documented or suspected treatment failure. Proviral DNA genotyping may be considered in complex cases (multiple prior failures, unavailable resistance history), but it is not a routine pre-switch requirement.

    Echoing EACS recommendations cited in the policy, routine proviral DNA genotyping for virologically suppressed persons is not recommended. Proviral assays can miss previous resistance or identify archived mutations of unclear significance; their use should be limited to select clinical situations and interpreted in context of prior resistance history and treatment course.

    Procedure and Billing Codes

    Antibody/antigen assay codesCPT
    86701Antibody; HIV-1.
    86702Antibody; HIV-2.
    86703Antibody; HIV-1 and HIV-2, single result.
    87389Infectious agent antigen detection by immunoassay technique (eg, EIA, ELISA, FIA, IMCA), qualitative or semiquantitative; HIV-1.
    Nucleic acid testing (HIV-1 and HIV-2)CPT
    87390Infectious agent antigen detection by immunoassay technique; HIV-1 antigen(s) with HIV-1 and HIV-2 antibodies, single result.
    87391Infectious agent antigen detection by immunoassay technique; HIV-2.
    87534Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique.
    87535Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique (includes reverse transcription when performed).
    87536Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification (includes reverse transcription when performed).
    87537Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique.
    87538Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique (includes reverse transcription when performed).
    87539Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification (includes reverse transcription when performed).
    Resistance/genotype and phenotype codesCPT | Proprietary
    87901Infectious agent phenotype analysis by nucleic acid with drug resistance tissue culture analysis, HIV-1; first through 10 drugs tested.
    87903Tissue culture analysis, HIV-1; first through 10 drugs tested (phenotype).
    87904Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion).
    87906Infectious agent (HIV), targeted viral next-generation sequence analysis (PR, RT, INT), algorithm reported as prediction of antiviral drug susceptibility.
    0219UProprietary test: Sentosa® SQ HIV-1 Genotyping Assay.
    HCPCS/G codes for screeningHCPCS
    G0432Infectious agent antibody detection by enzyme immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening.
    G0433Infectious agent antibody detection by enzyme-linked immunosorbent assay (ELISA).
    G0435Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening.
    G0475HIV antigen/antibody combination assay, screening.
    S3645HIV-1 antibody testing of oral mucosal transudate.
    Removed/Updated CPT CodesCPT
    86689CPT code removed from policy
    Other referenced codesmixed
    No codes listed
    Virological failure threshold
    Virological failure threshold200 copies/mL
    Evidence strength at higher levelsAI strength for >1,000 copies/mL
    Consideration for low-level viremiaTesting may be considered for confirmed HIV RNA 201-500 copies/mL (CIII); testing may be unsuccessful at some VLs but should still be attempted
    Biologically relevant change in viral load
    Biologically relevant change in viral load>= 0.5 log10 (threefold)
    Reasoning

    Actions for Providers — Documentation, Ordering, and Resistance Testing

    Prior Authorization

    Obtain genotyping/phenotyping for specified indications

    HIV genotyping or phenotyping meets coverage criteria for specified situations; providers must obtain genotypic and phenotypic testing prior to initiating doravirine and when indicated for treatment-experienced or failing regimens (e.g., suboptimal viral load reduction, noncompliance, acute/recent infection, ARV‑naïve entering care, pregnant individuals prior to ART or with detectable RNA).

    • Required prior to initiating doravirine therapy (genotyping and phenotyping is required).
    • Phenotyping meets coverage for treatment‑experienced individuals on failing regimens thought to have multidrug resistance.
    Prior Authorization

    Order genotypic resistance testing for initial care and virologic failure

    Order genotypic resistance testing at entry into care to guide initial ART and when virologic failure occurs (HIV‑RNA >200 copies/mL), and include integrase genotyping when INSTI resistance is suspected or prior CAB‑LA exposure occurred.

    • Genotypic testing recommended at entry into care (to guide selection of initial ART).

    Clinical Background and Rationale

    Background: Human immunodeficiency virus (HIV) is an RNA retrovirus that targets CD4+ lymphocytes and, if untreated, can progress to acquired immunodeficiency syndrome (AIDS). The policy notes that HIV-1 is the dominant global subtype with widely available quantitative RNA assays, whereas HIV-2 is less common and often associated with lower viremia and different diagnostic considerations. Viral load measurement (HIV-1 RNA) is central to diagnosis and management, and consistent use of assay platforms is recommended because inter-assay variability can affect comparability of results.

    Definitions and Key Terms

    HIV-1 / HIV-2 — distinctions and diagnostic implications
    HIV-1 vs HIV-2 distinctionHIV-1 is the dominant global subtype with established, quantitative RNA assays; HIV-2 is less common, often milder, and may have lower viremia
    Diagnostic implicationsHIV-1 RNA assays reliably quantify viremia; HIV-2 may not be reliably detected or quantified by many HIV-1 RNA assays—DNA testing is used to confirm HIV-2
    Epidemiology noteHIV-2 is most relevant in certain regions (e.g., Western Africa) and requires specific consideration when serology is indeterminate
    Genotypic and phenotypic resistance testing
    Genotypic testing detectsResistance-associated mutations in viral genes (protease, reverse transcriptase, integrase)
    Phenotypic testing measures
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHuman Immunodeficiency Virus (HIV)
    Policy CodePolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)
    Change TypeCoverage criteria revisions and code removal
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionOrder antigen/antibody combination assay (or rapid antibody test for PrEP populations) for screening and document risk factors and indication when requesting testing.
    SourceLink
    On This Page
    Coverage Criteria — Screening, Diagnostic, and Resistance TestingProcedure and Billing CodesActions for Providers — Documentation, Ordering, and Resistance TestingClinical Background and RationaleDefinitions and Key Terms
    Genotyping/phenotyping for HIV‑infected pregnant individuals before ART initiation or for those with detectable HIV RNA levels

    Genotypic testing recommended at entry to care in pregnancy; include integrase testing when INSTI exposure or concern

    Multidrug resistance: Phenotyping meets coverage for treatment‑experienced individuals on failing regimens suspected to have multidrug resistance

    Phenotypic testing added to genotypic when complex resistance patterns are suspected

    Strength of evidence stronger for >1,000 copies/mL; testing may be unsuccessful at some VL levels but should still be attempted

    Pregnancy and peripartum testing: Opt-out testing early in pregnancy with repeat in third trimester in increased-risk settings; expedited testing during labor when status undocumented with rapid resultsthird trimester retest when elevated risk or mandated by state

    If positive in labor, initiate intrapartum zidovudine prophylaxis and perform infant NAT

    PrEP-related recommendations: If person on PrEP has RNA ≥200 copies/mL, initiate ART immediately while confirming diagnosis; very low-positive RNA (<200 copies/mL) requires confirmatory testing prior to ART initiation>=200 copies/mL

    Consider HIV DNA testing when diagnostic testing inconclusive

    Review prior resistance results when changing therapy and document in the medical record

    Antibody and antigen/antibody testing should not be repeated more often than once every 90 days; nucleic acid testing should not be repeated more often than once every month.
    90 days / 1 month

    Consolidated into Note 1 per revision history

    Changes smaller than 0.5 log10 may reflect assay variability rather than true change in replication
    Clinical implicationRequire same-platform measurements to interpret meaningful changes
    Acute infection viral load consideration
    Acute infection RNA+ / Ab-negative definitionAny positive quantitative plasma HIV RNA in the setting of a negative or indeterminate antibody test is highly consistent with acute HIV infection
    Low-positive results guidanceEven HIV RNA levels <3,000 copies/mL can indicate very early acute infection; repeat testing on a new specimen to confirm
    Follow-up testingRepeat quantitative or qualitative HIV RNA testing and document seroconversion to confirm diagnosis
    Viral load monitoring intervals
    Initial monitoring after ART start/changeMeasure plasma viral load within 4–8 weeks after ART initiation or regimen change
    Frequency until suppressionRepeat every 4–8 weeks until below assay limit of detection
    Maintenance monitoringAfter suppression, measure every 3–4 months or extend to every 6 months for stable, adherent patients suppressed >1 year
    Resistance testing viral load threshold
    Resistance testing trigger (primary threshold)>200 copies/mL
    Higher-evidence thresholdAI evidence strength for >1,000 copies/mL
    Low-level viremia guidanceConfirmed HIV RNA 201-500 copies/mL: testing may be considered though success may be limited (CIII)
    Pregnancy viral load threshold for cesarean planning
    Cesarean planning viral load threshold>= 1,000 copies/mL
    Timing for third-trimester assessmentAssess viral load at 34–36 weeks for delivery planning
    Action if >=1000 at 37–38 weeksSchedule cesarean delivery for 38 weeks
    HIV-2 viral load threshold for resistance testing
    HIV-2 resistance testing threshold>= 500 copies/mL
    When to perform resistance testingAt diagnosis, prior to treatment initiation, and at virological failure when threshold met
    Monitoring cadence noteRepeat HIV-2 viral load if previously suppressed then becomes detectable; measure at 1, 3, 6 months after ART start/change then every 3–6 months
    Aptima HIV-1 Quant assay quantitation range
    Aptima HIV-1 Quant assay range30 to 10,000,000 copies/mL
    FDA statusFDA-approved for quantitation and diagnostic aid (dual use)
    Targets detectedQuantitates HIV-1 groups M, N, and O
    Antibody/Antigen retest interval
    Antibody/Antigen retest intervalNot more often than once every 90 days
    Purpose of limitConsolidated Note 1 to reduce unnecessary repeat testing and align with coverage criteria
    ApplicabilityApplies to antibody and antigen/antibody testing used for screening and follow-up per policy notes
    Nucleic acid testing retest interval
    Nucleic acid testing retest intervalNot more often than once every month
    Applies toQualitative or quantitative NAT used for diagnosis or monitoring
    RationaleConsolidated Note 1 frequency guidance to prevent excessive repeat NAATs
  1. Perform resistance testing for virologic failure (>200 copies/mL; stronger evidence at >1,000 copies/mL).
  2. Include INSTI genotyping if INSTI resistance is suspected or prior CAB‑LA exposure occurred.
  3. Prior Authorization

    Include INSTI genotyping (and phenotyping when complex)

    When ordering resistance testing for virologic failure or to guide regimen selection, ensure genotypic assays include INSTI sequencing when indicated; providers may need to order INSTI‑specific assays separately and consider adding phenotypic testing for complex resistance patterns.

    • Reverse transcriptase and protease genotypic testing should be performed for everyone with virologic failure; order integrase testing for INSTI‑based regimen failures.
    • Add phenotypic testing when complex mutation patterns are known or suspected.
    Billing Rule

    Use referenced procedure codes and follow PA rules

    Refer to the listed CPT/HCPCS and proprietary codes when submitting claims; follow payer prior authorization policies for advanced assays or phenotypic testing as applicable.

    • Codes listed include: 86701–86703, 87389–87391, 87534–87539, 87901, 87903–87904, 87906, 0219U, G0432–G0435, G0475, S3645.
    • Prior authorization may be required for certain resistance or phenotypic assays per payer rules.
    Denial Risk

    Do not use removed CPT code 86689 on claims

    The policy removed CPT code 86689; do not bill using this removed code — claims using 86689 may be denied or require recoding to current covered codes.

    • 86689 was removed from the policy's listed codes and may trigger denial or need recoding.
    • Use current covered CPT/HCPCS codes from the policy when submitting claims.
    Step Therapy

    Perform genotyping/phenotyping before doravirine

    Obtain genotyping and phenotyping prior to initiating doravirine; document genotypic testing and use phenotyping when treatment‑experienced patients are on failing regimens suspected to have multidrug resistance.

    • Genotyping and phenotyping are required prior to doravirine initiation.
    • Phenotyping meets coverage for treatment‑experienced individuals on failing regimens thought to have multidrug resistance.
    Note

    Start ART immediately for PrEP patients with RNA ≥200 copies/mL

    If HIV is suspected in a person on PrEP with HIV RNA ≥200 copies/mL, initiate an effective HIV treatment regimen immediately while awaiting confirmation of diagnosis.

    • Immediate initiation of effective ART is recommended for persons on PrEP with RNA ≥200 copies/mL while confirming diagnosis (AIII).
    • Very low‑positive RNA (<200 copies/mL) requires confirmatory testing before initiating ART.
    Documentation Required

    Do not require proviral testing for routine switches without failure

    Do not routinely require proviral (proviral DNA) resistance testing prior to switching suppressed patients to 2‑drug therapy unless there is documented or suspected treatment failure; switching from long‑acting CAB+rPV back to oral therapy does not require proviral testing if suppression maintained.

    • Proviral resistance testing is not required prior to switching to 2‑drug therapy unless documented/suspected treatment failure.
    • Switching from long‑acting cabotegravir plus rilpivirine back to daily oral therapy can be done without proviral DNA resistance testing in patients who have maintained suppression.
    Prior Authorization

    Initiate ART without waiting for resistance results

    Do not delay ART initiation while awaiting resistance test results; start ART promptly and modify the regimen later if resistance results indicate a change is needed.

    • ART initiation should not be delayed for resistance testing results; regimens can be modified once results are reported.
    • EACS and DHHS guidance support starting ART promptly and using resistance results to adjust therapy.
    Note

    Follow recent policy revisions and Change Log

    (See policy notes and revision history) Recent revisions added and clarified provider actions and testing criteria — review policy Change Log and Notes for details when ordering tests or performing prior authorization.

    • Revision history documents additions (CC3, CC4, CC9), frequency guidance moved into Note 1, and removal of CPT 86689.
    • Ensure claims and orders adhere to updated test‑type criteria and new notes.
    Billing Rule

    Adhere to testing frequency limits

    Antibody and antigen/antibody testing should not be repeated more often than once every 90 days; nucleic acid testing (qualitative or quantitative) should not be repeated more often than once every month.

    • Antibody/antigen retest interval: not more often than every 90 days (Note 1).
    • Nucleic acid testing retest interval: not more often than once every month (Note 1).
    Documentation Required

    Document viral load and CD4 timing/results in the record

    Document timing and results of viral load and CD4 testing in the medical record at entry into care, at ART initiation, and at recommended monitoring intervals to support medical necessity and coverage.

    • Document viral load and CD4 at entry into care and per DHHS monitoring schedule (e.g., 4–8 weeks after ART start, then every 3–4 months or up to 6 months if stable).
    • Document genotypic resistance testing performed before ART initiation and when virologic failure occurs.
    Documentation Required

    Review and document prior resistance results

    Review and document all prior and current drug‑resistance test results when designing a new antiretroviral regimen; include evidence of reviewed prior tests in the medical record when changing therapy after virologic failure.

    • All prior and current resistance results should be reviewed and considered when constructing a new regimen.
    • Documentation of reviewed prior tests should be included in the medical record when changing therapy after virologic failure.
    Documentation Required

    Document investigations for indeterminate serology and monitoring

    For indeterminate serology or inconclusive diagnostic testing, document investigation including PCR for HIV‑2 proviral DNA when indicated; document timing of viral load measurements and any resistance testing performed.

    • Investigate indeterminate HIV‑1 or HIV‑2 serology with PCR for HIV‑2 proviral DNA.
    • Document viral load monitoring per schedule and document resistance testing when viral load thresholds are met.
    Documentation Required

    Document risk factors and indication when ordering tests

    When ordering tests such as PrEP initiation/maintenance screening or testing after suspected exposure, document the patient's risk factors and specific indication (see Note 2) to support medical necessity.

    • Document elevated‑risk factors (e.g., MSM, multiple partners, injection drug use, transactional sex, prior/concurrent STI/hepatitis/TB) per Note 2.
    • Include the indication (PrEP initiation/maintenance, suspected recent exposure, positive/indeterminate screen) on the order and in the medical record.
    Denial Risk

    Avoid non‑rapid antibody‑only screening tests

    Screening with an antibody test that is non‑rapid and lacks an antigen component DOES NOT MEET COVERAGE CRITERIA; ordering such tests risks denial of coverage.

    • Explicit policy statement: antibody test that does not provide rapid results and does not incorporate antigen testing does not meet coverage criteria (CC9).
    • Antigen testing alone is also noncovered per revision history; use antigen/antibody combination assays or rapid antibody tests where indicated.
    Documentation Required

    Attempt and document resistance testing even if VL >500 copies/mL

    Even if HIV‑RNA is >500 copies/mL (where genotyping may be unsuccessful), attempt drug‑resistance testing and document inability to obtain a genotype if unsuccessful; failure to attempt recommended testing may affect coverage of regimen changes.

    • Drug‑resistance testing may be unsuccessful when HIV‑RNA levels are >500 copies/mL but should still be considered.
    • If testing is unsuccessful, document attempts and rationale in the medical record to support subsequent treatment decisions.
    Prior Authorization

    Order resistance testing at virologic failure threshold (>200 copies/mL)

    Order resistance testing for patients on combination ART with confirmed HIV‑RNA >200 copies/mL (AI); consider testing at 201–500 copies/mL and recognize evidence is stronger at >1,000 copies/mL.

    • Recommended trigger: HIV‑RNA >200 copies/mL for virologic failure; AI strength for >1,000 copies/mL; consider testing at 201–500 copies/mL.
    • Perform resistance testing while patient is on ART or within 4 weeks of stopping non‑long‑acting agents.
    Prior Authorization

    Perform resistance testing for HIV‑2 at ≥500 copies/mL

    Perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure for HIV‑2 when viral load meets or exceeds ≥500 copies/mL; omission when indicated may risk denial.

    • HIV‑2 resistance testing threshold: ≥500 copies/mL for testing at diagnosis, prior to treatment initiation, and at virological failure.
    • Document testing and results in the chart to support medical necessity.
    Denial Risk

    Do not order antigen‑only tests for screening

    Ordering HIV antigen testing alone (independent of antigen/antibody testing) does not meet coverage and will trigger noncoverage; use an antigen/antibody combination assay or rapid antibody test per policy.

    • Antigen‑alone testing is explicitly stated as not meeting coverage criteria.
    • Use approved antigen/antibody combination assays or rapid antibody tests for screening where indicated.
    Billing Rule

    Claims using removed CPT 86689 may be denied

    Claims submitted using removed CPT code 86689 may be denied or require recoding; update billing to current listed CPT/HCPCS codes in the policy.

    • 86689 was removed from the policy's applicable procedure codes and may trigger claim denial.
    • Ensure claims use current CPT/HCPCS codes listed in the policy (see code table).
    Drug susceptibility (fold-change in drug inhibition) often using recombinant virus assays
    When to use eachGenotypic preferred for most patients; add phenotypic testing for known or suspected complex resistance patterns
    Acute HIV infection — definition
    Definition of acute HIV infectionDetection of HIV RNA in the presence of a negative or indeterminate antibody test (RNA+ with Ab-/indeterminate)
    Diagnostic actionAny positive quantitative plasma HIV RNA in this setting is highly consistent with acute infection; repeat on a new specimen to confirm
    Window considerationsLow-level RNA (<3,000 copies/mL) may occur very early and still indicate acute infection
    Virologic failure — definition and thresholds
    Virologic failure definitionPersistent HIV-RNA >200 copies/mL
    Graded recommendationsStronger recommendation for testing at >1,000 copies/mL; consider at 201-500 copies/mL though testing may be less successful
    Testing timingPerform resistance testing while on ART or within 4 weeks of stopping non-long-acting agents
    Nucleic Acid Test (NAT) — definition/usage note
    NAT definition/usageNucleic acid tests (NAT) detect HIV RNA and can usually detect infection 10–33 days after exposure; qualitative NATs are FDA-approved for diagnosis in antibody-negative persons
    Role in algorithmUse NAT when Ab/Ag assays are negative/indeterminate with high suspicion or to confirm reactive antibody tests
    LimitationsHIV-1 RNA tests do not detect HIV-2; DNA testing may be needed for HIV-2 confirmation
    INSTI resistance testing — definition
    INSTI resistance testing definitionGenotypic assay that includes the integrase gene to detect transmitted or acquired INSTI resistance
    When to orderOrder when transmitted INSTI resistance is suspected, after CAB-LA exposure, or for virologic failure on INSTI-based regimens
    Ordering noteINSTI-specific assays may need to be ordered separately from standard genotypic panels
    Investigation of indeterminate serology
    Indeterminate serology investigationWhen HIV-1 or HIV-2 serology is indeterminate, perform PCR for HIV-2 proviral DNA to establish presence or absence of HIV-2 infection
    Documentation requiredDocument investigation steps including PCR results when ordering further testing or resistance assays
    ContextRecommended when serology does not fit a clear confirmed diagnosis
    Viral load monitoring schedule
    Monitoring cadence after ART start/changeIf pre-treatment viral load detectable: measure at 1, 3, and 6 months after ART start/change, then every 3–6 months; if pre-treatment undetectable: measure at 1 month then every 6 months
    Early response monitoringMeasure within 4–8 weeks after ART initiation and repeat every 4–8 weeks until suppressed
    Stable suppression intervalAfter suppression, every 3–4 months or extend to 6 months for stable adherent patients suppressed >1 year
    Resistance testing threshold (HIV-2)
    HIV-2 resistance testing threshold>= 500 copies/mL
    IndicationsPerform at diagnosis, prior to treatment initiation, and at virological failure when threshold met
    Monitoring linkRepeat viral load and perform resistance testing if HIV-2 becomes repeatedly detectable after maximal suppression
    Testing interval limits — Note 1 guidance
    Antibody/antigen retest limitNot more often than once every 90 days
    NAT retest limitNot more often than once every month
    Policy locationConsolidated into Note 1 per revision history
    Elevated-risk factors — Note 2 list
    Elevated-risk factors to documentMSM; MSM/W; transgender individuals; sexual contact with a person with HIV; multiple sexual partners since last test; sharing injection equipment; transactional sex; prior/concurrent STI, hepatitis, or tuberculosis; sex with individuals of unknown risk
    When requiredProviders should document these risk factors and the indication when ordering antigen/antibody, rapid antibody, or NAT testing
    PurposeSupports medical necessity and appropriate application of screening and retesting intervals